Scinai Immunotherapeutics Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Scinai Immunotherapeutics Ltd. generated cash of -$9,382,000, which is less than the previous year. Cash used in financing activities reached the amount of $1,086,000 last year. Net change in cash is therefore -$9,205,000.
Cash Flow
| 2014 | -7.57M | -180K | -782K |
|---|---|---|---|
| 2015 | -2.63M | -11.03K | 8.66M |
| 2016 | -9.65M | -7.81M | 0 |
| 2017 | -2.88M | 1.94M | 17.77M |
| 2018 | -57.19M | -23.45M | 84.32M |
| 2019 | -22.31M | -2.08M | 24.67M |
| 2020 | -72.53M | -5.93M | 13.71M |
| 2021 | -24.48M | -361K | 67.78M |
| 2022 | -7.26M | -836K | 6.77M |
| 2023 | -9.38M | -637K | 1.08M |
SCNI Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 14.21M | 17.51M | 9.42M | 72.46M | 20.29M | 71.38M | 4.07M | 33.47M | 2.46M | 17.86M |
Operating activities | ||||||||||
Net income | -6.5M | -5.79M | -39.97M | -4.45M | -31.62M | -87.72M | -9.92M | -9.18M | -2.61M | -7.76M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 514K | 562K | 2.41M | 2.43M | 476.35K | 260K | 126.45K | 621K | 161.17K | 677K |
Stock-based compensation expense | 1.13M | 1.60M | 2.75M | 2.94M | 1.06M | 0 | 149.15K | 1.26M | 191.19K | 363K |
| Deferred income tax benefit | 1.13M | 1.60M | 2.75M | 2.94M | 1.06M | 0 | 149.15K | 1.26M | 191.19K | 363K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -290K | 140K | 0 | 0 | 89.47K | 0 | -893.20K | 0 | -190.94K | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 0 | 1.23M | -15.19M | 0 | 14.5M | 0 | -238K | 0 | 132K |
Cash generated by operating activities | -9.38M | -7.26M | -24.48M | -72.53M | -22.31M | -57.19M | -2.88M | -9.65M | -2.63M | -7.57M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | -112.62K | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -637K | -836K | -430K | -6.13M | -2.15M | -23.73M | -1.29M | -20K | -8.72K | -30K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -637K | -836K | -361K | -5.93M | -2.08M | -23.45M | 1.94M | -7.81M | -11.03K | -180K |
Financing activities | ||||||||||
Common Stock Issued | 139K | 0 | 69.00M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -1.22M | -1.24M | 4.27M | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 1.08M | 6.77M | 67.78M | 13.71M | 24.67M | 84.32M | 17.77M | 0 | 8.66M | -782K |
Net Change In Cash | -9.20M | -3.30M | 44.61M | -63.04M | 693.11K | 4.50M | 16.43M | -17.76M | 6.12M | -8.25M |
Cash at end of period | 5.01M | 14.21M | 54.03M | 9.42M | 20.98M | 75.88M | 20.51M | 15.70M | 8.58M | 9.61M |